72 related articles for article (PubMed ID: 24450768)
1. Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.
Boggs JW; Hop CE; McNamara E; Deng Y; Messick K; West K; Choo EF
Mol Pharm; 2014 Mar; 11(3):1062-8. PubMed ID: 24450768
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the metabolism of midazolam in C57BL/6J and hepatic reductase null (HRN) mice.
Grimsley A; Foster A; Gallagher R; Hutchison M; Lundqvist A; Pickup K; Wilson ID; Samuelsson K
Biochem Pharmacol; 2014 Dec; 92(4):701-11. PubMed ID: 25450676
[TBL] [Abstract][Full Text] [Related]
3. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
[TBL] [Abstract][Full Text] [Related]
5. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
[TBL] [Abstract][Full Text] [Related]
6. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
[TBL] [Abstract][Full Text] [Related]
7. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity.
Henderson CJ; Pass GJ; Wolf CR
Toxicol Lett; 2006 Mar; 162(1):111-7. PubMed ID: 16343823
[TBL] [Abstract][Full Text] [Related]
8. Application of hepatic cytochrome b
Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
[TBL] [Abstract][Full Text] [Related]
9. Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system.
Henderson CJ; McLaughlin LA; Wolf CR
Mol Pharmacol; 2013 Jun; 83(6):1209-17. PubMed ID: 23530090
[TBL] [Abstract][Full Text] [Related]
10. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice.
Stiborova M; Cerna V; Moserova M; Arlt VM; Frei E
Neuro Endocrinol Lett; 2013; 34 Suppl 2():43-54. PubMed ID: 24362092
[TBL] [Abstract][Full Text] [Related]
11. Deletion of cytochrome P450 oxidoreductase enhances metabolism and DNA adduct formation of benzo[a]pyrene in Hepa1c1c7 cells.
Reed L; Jarvis IWH; Phillips DH; Arlt VM
Mutagenesis; 2019 Dec; 34(5-6):413-420. PubMed ID: 31612222
[TBL] [Abstract][Full Text] [Related]
12. The usage of a three-compartment model to investigate the metabolic differences between hepatic reductase null and wild-type mice.
Hill L; Chaplain MAJ; Wolf R; Kapelyukh Y
Math Med Biol; 2017 Mar; 34(1):1-13. PubMed ID: 26443812
[TBL] [Abstract][Full Text] [Related]
13. Defective bile salt biosynthesis and hydroxylation in mice with reduced cytochrome P450 activity.
Kunne C; Acco A; Hohenester S; Duijst S; de Waart DR; Zamanbin A; Oude Elferink RP
Hepatology; 2013 Apr; 57(4):1509-17. PubMed ID: 23184615
[TBL] [Abstract][Full Text] [Related]
14. Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system.
Finn RD; McLaren AW; Carrie D; Henderson CJ; Wolf CR
J Pharmacol Exp Ther; 2007 Jul; 322(1):40-7. PubMed ID: 17435107
[TBL] [Abstract][Full Text] [Related]
15. The hepatic reductase null mouse as a model for exploring hepatic conjugation of xenobiotics: application to the metabolism of diclofenac.
Pickup K; Gavin A; Jones HB; Karlsson E; Page C; Ratcliffe K; Sarda S; Schulz-Utermoehl T; Wilson I
Xenobiotica; 2012 Feb; 42(2):195-205. PubMed ID: 21955249
[TBL] [Abstract][Full Text] [Related]
16. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
Gu J; Chen CS; Wei Y; Fang C; Xie F; Kannan K; Yang W; Waxman DJ; Ding X
J Pharmacol Exp Ther; 2007 Apr; 321(1):9-17. PubMed ID: 17218484
[TBL] [Abstract][Full Text] [Related]
17. The disruption of hepatic cytochrome p450 reductase alters mouse lipid metabolism.
Mutch DM; Klocke B; Morrison P; Murray CA; Henderson CJ; Seifert M; Williamson G
J Proteome Res; 2007 Oct; 6(10):3976-84. PubMed ID: 17722906
[TBL] [Abstract][Full Text] [Related]
18. Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine.
Zhang QY; Kaminsky LS; Dunbar D; Zhang J; Ding X
Drug Metab Dispos; 2007 Sep; 35(9):1617-23. PubMed ID: 17567730
[TBL] [Abstract][Full Text] [Related]
19. UHPLC-MS-Based Lipidomic and Metabonomic Investigation of the Metabolic Phenotypes of Wild Type and Hepatic CYP Reductase Null (HRN) Mice.
Gray N; Gethings LA; Plumb RS; Wilson ID
J Pharm Biomed Anal; 2020 Jul; 186():113318. PubMed ID: 32380354
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
